Maternally inherited diabetes and deafness (MIDD) most commonly results from heteroplasmic G to A substitution of the mitochondrial DNA at nucleotide pair 3243 in one of the two tRNA(Leu) genes. The same mutation that causes MIDD also causes a syndrome of severe neuromuscular disease called MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke). Within a family there is usually a dominant phenotype, although occasionally some members develop MIDD whilst others develop MELAS.

CGMS use is on the uptake as more and more insurers, including Medicare, see the value of constant knowledge of glucose levels and trending changes that can help prevent hypo- and hyperglycemia before they occur. There is no doubt that CGMS will eventually replace finger sticks for many patients as …

Diabetes in Control is pleased to bring you an exclusive interview with Dr. Andrew Stewart. Dr. Stewart and his fellow researchers at the Icahn School of Medicine at Mount Sinai have discovered a novel combination of two classes of drugs that induces the highest rate of proliferation ever observed in adult human beta cells—the cells in the pancreas that produce insulin. The result is an important step toward a diabetes treatment that restores the body’s ability to produce insulin. 

Time in glycemic range inversely correlated to risk of developing vascular complications in patients with diabetes

Study finds relationship between diabetes and OSA cofactors in development of CVD.

Study strengthens existing dietary advice that patients should switch from products made from white flour to whole grains.

Rise Study compared gastric banding to metformin in preserving beta cell functions in people who have prediabetes.

Research shows urological issues more frequent than once thought.

Which of the following ADA statements about recommended treatment algorithms for type 2 diabetes is true?

A. The ADA algorithm includes a specific hierarchy of recommended therapies while the AACE algorithm does not.
B. The ADA’s algorithm specifies agents to be considered for cardiovascular risk reduction.
C. Both AACE and the ADA stratify the choice of initial therapy according to baseline HbA1C less than 7.5% or greater than/equal to 7.5%.
D. The risk-benefit profiles of antihyperglycemic classes are not reflected in the AACE or ADA algorithm.

Follow the link for the answer.

Have you provided all your new patients who take insulin with a prescription for Glucagon or similar product? Follow the link to see how you and your colleagues compare.